Gentex Corp: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 4, 2022 and accepted by EDGAR at Nov 4, 2022, 09:45 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $493.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $1.43bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-07-01 to 2022-09-30 | $346.4m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2022-01-01 to 2022-09-30 | $969.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2022-07-01 to 2022-09-30 | $147.2m | us-gaap:GrossProfit |
| Gross profit | 9 months2022-01-01 to 2022-09-30 | $456.0m | us-gaap:GrossProfit |
| Research and development | 3 months2022-07-01 to 2022-09-30 | $33.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-01-01 to 2022-09-30 | $98.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-07-01 to 2022-09-30 | $26.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-01-01 to 2022-09-30 | $81.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | $86.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | $275.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-07-01 to 2022-09-30 | $13.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-01-01 to 2022-09-30 | $41.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-07-01 to 2022-09-30 | $72.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | $232.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | $0.31 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | $0.99 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | $0.31 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | $0.99 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 231,617,017 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 231,529,453 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | $236.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $108.5m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months2022-01-01 to 2022-09-30 | $84.9m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2022-01-01 to 2022-09-30 | $83.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-09-30 | $222.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $989.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $2.31bn | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $265.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $277.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-09-30 | $2.03bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000355811-22-000043. Last ingested by Listed: Nov 6, 2026, 14:07 ET. Listed shows no prices and gives no investment advice.